Deficiencies in immunoassay methods used to monitor serum Estradiol levels during aromatase inhibitor treatment in postmenopausal breast cancer patients

SpringerPlus

Volumn 2, Issue 1, 2013, Pages 1-6

  Jaque, Jenny ^a   Macdonald, Heather ^a   Brueggmann, Doerthe ^a   Patel, Sherfaraz K ^a   Azen, Colleen ^a   Clarke, Nigel ^b   Stanczyk, Frank Z ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84876544579     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-2-5     Document Type: Article

References (9)

1. Coates AS, Keshaviah A, Thurlimann B et al (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25:486-492
2. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45-53
3. Howell A, Cuzick J, Baum M et al (2005) Result. s of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62
4. Santen RJ, Demers L, Ohorodnik S, Settlage J, Langecker P, Blanchett D, Goss PE, Wang S (2007) Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids 72:666-671
5. Stanczyk FZ, Clarke NJ (2010) Advantages and challenges of mass spectrometry assays for steroid hormones. J Steroid Biochem Mol Biol 121:491-495
6. Stanczyk FZ, Jurow J, Hsing AW (2010) Limitations of direct immunoassays for measuring circulating estradiol levels in postmenopausal women and men in epidemiologic studies. Cancer Epidemiol Biomark Prev 19:903-906
7. Stanczyk FZ, Cho MM, Endres DB, Morrison JL, Patel S, Paulson RJ (2003) Limitations of direct estradiol and testosterone immunoassay kits. Steroids 68:1173-1178
8. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A (2011) Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 103:1299-1309
9. Dowsett M, Cuzick J, Ingle J et al (2010) Meta-analysis of breast cancer outcomes in adjuvant trials for aromatase inhibitors versus tamoxifen. J Clin Oncol 28 (3):509-518